Article Text

Download PDFPDF
Early invasive strategy should be performed within 72 hours in high-risk patients with non-ST-elevation myocardial infarction
  1. Carlos Collet1,
  2. Patrick W Serruys2
  1. 1 Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, North Holland, The Netherlands
  2. 2 Department of Cardiology, Imperial College London, London, UK
  1. Correspondence to Professor Patrick W Serruys, Department of Cardiology, Imperial College London, London SW7 2AZ, UK; patrick.w.j.c.serruys{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: Jobs A, Mehta SR, Montalescot G, et al. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. Lancet 2017;390:737–46.


The mainstay of treatment for patients presenting with non-ST-elevation acute coronary syndrome (NSTE-ACS) is medical therapy, early coronary angiography and revascularisation. A routine invasive strategy has been shown to reduce all-cause death and myocardial infarction  compared with a conservative approach at 5 years.1 Therefore, an early invasive strategy with intent to perform revascularisation is advocated in the 2014 American and European guidelines with a class I recommendation.2 3 While immediate angiography is recommended for extremely high-risk patients (eg, haemodynamic or electrical instability, persistent angina, heart failure or worsening mitral regurgitation), the optimal timing for an invasive approach in patients …

View Full Text


  • Competing interests PWS is a member of the international advisory board of Abbott Vascular.

  • Provenance and peer review Commissioned; internally peer reviewed.